Objective: In August 2011, South Africa expanded its adult antiretroviral therapy (ART) guidelines to allow treatment initiation at CD4 cell values 350 cells/ml or less. Mortality and morbidity are known to be reduced when initiating at higher CD4 levels; we explored the impact on patient loss to follow-up.
Introduction
South Africa's national antiretroviral therapy (ART) program, launched in 2004, is the world's largest [1] , with 1.8 million individuals initiated on ART by mid-2011 [2] . Initially, the threshold for ART eligibility in the national guidelines for adult ART initiation was set at a CD4 cell count below 200 cells/ml or a WHO Stage IV clinical condition [3] . In late 2009, the WHO revised their guidelines by increasing the threshold for eligibility for ART in resource-limited settings to 350 cells/ml or less [4, 5] . In August 2011, South Africa officially adopted this policy [6] . It has been estimated that this policy expanded eligibility to an additional 1.06 million [95% confidence interval (CI) 0.88-1.29 million] ART-naive adults with CD4 values 200-349 cells/ml [2] .
Patients who initiate ART with a CD4 cell count above 200 cells/ml are at reduced risk of death and serious opportunistic infections including tuberculosis (TB), as demonstrated in developed countries [7] [8] [9] , a randomized trial in Haiti [10] , and observational studies in sub-Saharan Africa [11] [12] [13] [14] . However, if patients initiate treatment before perceiving the clinical necessity, gains from positive clinical outcomes from earlier treatment may be offset by increases in patient loss to follow-up [15] .
To date, only one study has reported the effect of initiation at higher CD4 cell counts on loss to follow-up under routine early initiation (350 cells/ml) within sub-Saharan Africa and found 39% reduced loss among those initiating at CD4 cell counts more than 200 cells/ml versus 200 cells/ml or less [adjusted hazard ratio (aHR) 0.61, 95% CI 0.43-0.87] [11] .
Witkoppen Health and Welfare Centre (Witkoppen) is an NGO-operated clinic serving a primarily poor population from formal and informal settlements in northern Johannesburg, South Africa. In March 2010, a year before the national policy was enacted, Witkoppen began ART initiation for all adult patients at the higher threshold of 350 cells/ml or less. This provides a unique opportunity to examine the impact of initiating treatment among patients presenting at higher CD4 cell counts on patient loss to follow-up under routine care.
Methods
We created a retrospective cohort of all adult (18 years) ART-naive patients initiating ART at Witkoppen during April to December 2010 who presented with a baseline CD4 cell value eligible for ART (350 cells/ml). We excluded 29 patients missing a baseline CD4 cell value, leaving 1430 for analysis. Data were extracted from the clinic's electronic patient record system (TherapyEdge-HIV) in May 2012, allowing all participants time to experience a 12-month outcome. Clinic visits following ART initiation typically are scheduled monthly until the patient is considered stable and adherent (usually 5-6 months after initiation), at which time patients may be asked to return every 3-6 months. Patients who provided a South African ID number (n ¼ 685, 47.9%) were matched to the National Population Register of the South African Department of Home Affairs in August 2011 to identify deaths. We conducted a sensitivity analysis restricted only to patients with a valid South African ID number, but this did not change the size of our effect or our conclusions.
We sought to estimate the effect of initiating ART with a CD4 cell count 201-350 versus 200 cells/ml or less on loss to follow-up (primary outcome) in the first 12 months after ART initiation. We defined loss to followup as not returning to the clinic within 3 months of the patient's last missed scheduled visit. For loss to follow-up, person-time began accumulating 3 months after ART initiation (when patients became at risk for loss) and excluded 50 patients who died or transferred in the first 3 months. Person-time ended at death within 12 months, or the earliest of 12 months of follow-up, loss to followup, or transfer. For outcomes of death and incident TB, person-time began accumulating at ART initiation. We defined baseline CD4 cell count (200 and 201-350 cells/ml) as the temporally last measure between 6 months prior and 7 days after ART initiation and grouped patients into those who presented and initiated ARTwith a lower (200 cells/ml) or higher (201-350 cells/ml) baseline CD4 cell value.
We produced crude Kaplan-Meier curves of time to loss by CD4 cell group. We used Cox proportional hazards regression to estimate the association of CD4 cell category and 12-month loss to follow-up and report aHRs and 95% CIs. We also evaluated the impact of death on estimates of loss using a competing risks analysis and report the subdistribution hazard ratio (sHR) and 95% CI.
We identified pregnancy at ART initiation as an effect measure modifier of the relation between CD4 cell count and loss to follow-up by stratifying estimates of the risk of loss by CD4 cell group, gender, and pregnancy. Based on prior knowledge and change-in-estimate evaluation, we adjusted models for age, nationality, employment, and prevalent TB. The study was approved by institutional review boards at the University of North Carolina at Chapel Hill and the University of the Witwatersrand.
Results
Among the 1430 patients, nearly half (48.0%) presented with a CD4 cell count 201-350 cells/ml at ART initiation (Web Appendix 1). Median [interquartile range (IQR)] baseline CD4 cell count by group was 105 cells/ ml (55-154) versus 268 cells/ml (239-307). The higher CD4 cell count group was more likely to be less than 30 years old (31.7 versus 24.5%) and women (75.7 versus 63.4%), partly because there were more pregnant women (19.2 versus 10.6%) in the higher CD4 cell group due to routine antenatal HIV testing. The low CD4 cell count group had more TB at ART initiation (16.7 versus 5.7%).
Within 1 year of ART initiation, 15.5% (95% CI 13.0-18.2%) versus 12.7% (95% CI 10.3-15.3%) were lost among those in the lower versus the higher CD4 cell group, respectively ( Fig. 1 ). Among nonpregnant women, we found a 42% reduction in loss to followup among women initiating ART at higher versus lower CD4 cell counts (aHR 0.58; 95% CI 0.37-0.91; Table 1 ). Men who initiated ART at higher CD4 cell counts were also at reduced risk of loss to follow-up compared to men who started ART at CD4 cell count 200 cells/ml or less (aHR 0.74; 95% CI 0.44-1.23). However, among pregnant women, there was no association between Probability of not being lost to follow-up CD4 cell category and loss to follow-up (aHR 0.95; 95% CI 0.55-1.67). Additionally, younger adults (age 18-29 years) were 38% more likely to become lost to follow-up compared to adults aged 30-39 years (aHR 1.38, 95% CI 1.00-1.92), and unemployed patients were 51% (aHR 1.51, 95% CI 1.34-2.00) more likely to become lost to follow-up. Estimates differed little when accounting for death as a competing risk. Figure 1 shows the gender variation in loss to follow-up: men were more likely to be lost than nonpregnant women and women pregnant at ART initiation were most likely to be lost. 
Discussion
This is the first study from a routine clinical setting in South Africa to demonstrate patients can be initiated on ART at higher CD4 cell counts without increasing patient attrition. We found 42% (aHR 0.58; 95% CI 0.37-0.91) reduced risk of loss to follow-up among nonpregnant women and 26% (aHR 0.74; 95% CI 0.44-1.23) reduced risk among male patients who initiated ART at CD4 cell counts 201-350 cells/ml compared to those at 200 cells/ml or less. This result is in concert with a 39% reduced loss among those initiating at CD4 cell counts more than 200 cells/ml versus 200 or less in Lesotho [11] . However, our study highlights substantial variation by gender in reduced risk at initiating at higher CD4 cell counts. The association of initiating at higher CD4 cell counts was greatest among nonpregnant women and men, and null among pregnant women. Patient loss is a major challenge to providing effective HIV care and our results suggest that expanding ART eligibility to patients with higher baseline CD4 cell values can be done without increasing loss.
We found that loss to follow-up among men of both CD4 cell groups was substantially higher than nonpregnant women who initiate at CD4 cell count 201-350 cells/ml (Fig. 1) . Previous studies also have noted higher loss among men [16] [17] [18] , which suggests the need for specific retention interventions targeted to men. Loss to followup among women pregnant at ART initiation was the highest of any gender group, but interestingly, baseline CD4 cell count did not substantially affect loss among pregnant women, possibly because loss was already so high. High loss to follow-up among pregnant women recently has been reported in other studies within South Africa [18, 19, 20] and is particularly concerning as HIV is the largest cause of maternal mortality in South Africa [21] .
Additionally, our results confirm the considerable reductions in mortality and incident TB throughout the first year of ART seen among patients who present for 648 AIDS 2013, Vol 27 No 4 care and initiate ARTwith a higher CD4 cell count versus those who present with advanced immunosuppression. These findings correspond with those of several studies in resource-limited settings that observed significantly reduced risk of death and opportunistic infections when initiating treatment at higher CD4 cell values [10] [11] [12] [13] [14] and support South Africa's decision to revise its ART guidelines in 2011 to align with WHO recommendations.
Our study has several strengths. The unique study site allowed us to examine the impact of initiating at higher CD4 cell values within the context of routine, clinical care. Additionally, our analysis assessed the potential for the competing risk of death to bias our associations, but found little evidence of an important influence. We reduced the likelihood of death being misclassified as loss to follow-up by validating deaths using South Africa's national death registry and conducting a sensitivity analysis of our primary outcome. However, the registry only includes patients with a valid South African ID number (47.9%) and included only deaths through data export in August 2011; thus, it is possible that our estimate of mortality -particularly among patients lacking an ID number -may be underestimated.
Limitations to our analysis include use of data obtained from a single site and, therefore, findings may not be generalizable to all public-sector settings within South Africa or healthcare centers in other regions. As with most retention studies, we cannot know whether a patient continued care at another facility due to unlinked data at facilities. Thus, loss to follow-up in this study must be understood as lost to the facility where ARTwas initiated. It is important not to interpret our results as evidence for when to start ART (i.e. a comparison of whether or not to initiate patients when their CD4 cell count first falls 350 or defer until CD4 cell counts reach <200). Our results only pertain to what happens to patients once they are diagnosed and initiate ARTat their initial presentation CD4 cell value.
Our results show that adult, nonpregnant patients presenting for care and initiating ART at 201-350 cells/ ml have reduced loss to follow-up than those presenting and initiating ART at 200 cells/ml or less, with significant variation by gender and pregnancy status. These are the first results to show South Africa's 2011 expansion of ART treatment guidelines can be enacted without increasing attrition among patients initiating at higher CD4 cell values. As data become available from more sites that adopted the policy of initiating ART at higher CD4 cell counts, it will be important to perform similar evaluations at other sites in South Africa and other countries. Such information will be invaluable to national HIV/ AIDS programs looking for guidance about the implications of earlier ART initiation and may inform future expansions of the ART treatment criteria in South Africa.
